CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
FSRT combined with Bevacizumabcombination
Likely dose
FSRT combined with Bevacizumab 7.5mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04345146
NCT04345146Phase 2Completed
CompareCT.gov

A Prospective, Phase II Study of Bevacizumab Combined With Fractionated Stereotactic Radiotherapy in Patients With 1 to 10 Brain Metastases From Non-small Cell Lung Cancer

Sun Yat-sen University·interventional·Posted Apr 14, 2020·Updated Aug 28, 2023

In Brief

A Phase 2 clinical trial evaluating FSRT combined with Bevacizumab for Non-small Cell Lung Cancer. Completed, enrolled 100 participants across 1 site.

Detailed Summary

This Phase II randomized study is to determine the efficacy and safety of Bevacizumab combined with fractionated stereotactic radiation therapy(FSRT) in patients with 1 to 10 brain metastases in non-small cell lung cancer by assessing the treatment response, perilesional edema, neurological symptoms and quality of life.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 14, 2020
Enrollment StartJan 1, 2020
Primary CompletionMar 31, 2023
TodayJul 1, 2026
Enrollment to primary: 3.3 yearsPosted 6.2 years ago

Interventions

FSRT combined with Bevacizumabcombination

Bevacizumab: Patients will receive Bevacizumab (7.5mg/kg, q3w, IV) before and after FSRT. Fractionated stereotactic radiotherapy(FSRT): 40 Gy/10 fractions or 30 Gy/5 fractions for GTV will be delivered to brain metastases.